Rui Avelar
2022
In 2022, Rui Avelar earned a total compensation of $1.3M as Chief Medical Officer and Head of Research and Development at Evolus, a 2% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $202,400 |
|---|---|
| Option Awards | $290,381 |
| Salary | $469,000 |
| Stock Awards | $292,498 |
| Other | $10,633 |
| Total | $1,264,912 |
Avelar received $469K in salary, accounting for 37% of the total pay in 2022.
Avelar also received $202.4K in non-equity incentive plan, $290.4K in option awards, $292.5K in stock awards and $10.6K in other compensation.
Rankings
In 2022, Rui Avelar's compensation ranked 2,575th out of 5,753 executives tracked by ExecPay. In other words, Avelar earned more than 55.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,575 out of 5,753 | 55th |
Division Manufacturing | 1,429 out of 3,133 | 54th |
Major group Chemicals And Allied Products | 650 out of 1,419 | 54th |
Industry group Drugs | 604 out of 1,320 | 54th |
Industry Pharmaceutical Preparations | 434 out of 966 | 55th |
Source: SEC filing on May 8, 2023.
Avelar's colleagues
We found three more compensation records of executives who worked with Rui Avelar at Evolus in 2022.